FRANKFURT (Reuters) – Roche said it had abandoned certain drug development projects or acquisitions under consideration because of planned price cuts in best-selling prescription medicines in the United States.
Speaking in a media call after the release of first-half results, CEO Thomas Schinecker said the Swiss group was not taking the lead on any legal action against the U.S. government project under the Inflation Reduction Act (IRA), because other large drugmakers were much more severely affected, but its work on new drugs was impacted still.
“We have decided that we are not going to do certain trials, or that we are not going to do a merger or acquisition or licensing (deal) because it is becoming financially not viable,” said Schinecker. He declined to elaborate.
(Reporting by Ludwig Burger; Editing by Miranda Murray)